Does breast cancer associated with CHEK2 1100delC carry characteristics of basal phenotype?

By Dede Didem   Sari Ebru   Bulut Nilufer   Altundag Kadri  

Breast Cancer Research and Treatment, Vol. 103, Iss. 3, 2007-07 ,pp. : 371-371

Springer Publishing Company

Access to resources Recommend Favorite

Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?

By Ohno Shinji  

Breast Cancer, Vol. 19, Iss. 3, 2012-07 ,pp. : 212-217

Springer Publishing Company

Access to resources Recommend Favorite

Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?

By Galimberti Viviana  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 819-825

Springer Publishing Company

Access to resources Recommend Favorite

Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?

By Ogston Keith   Miller Iain   Schofield Andrew   Spyrantis Andreas   Pavlidou Eleni   Sarkar Tarun   Hutcheon Andrew   Payne Simon   Heys Steven  

Breast Cancer Research and Treatment, Vol. 86, Iss. 2, 2004-07 ,pp. : 181-189

Springer Publishing Company

Access to resources Recommend Favorite

Can bone markers guide more effective treatment of bone metastases from breast cancer?

By Clemons Mark   Cole David   Gainford Mary  

Breast Cancer Research and Treatment, Vol. 97, Iss. 1, 2006-05 ,pp. : 81-90

Springer Publishing Company

Access to resources Recommend Favorite